New York, United States , April 20, 2023 (GLOBE NEWSWIRE) -- The Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Size is to grow from USD 170 Billion in 2022 to USD 360 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period.
Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1711
List of Key Companies
- Kowa Company, Ltd.
- Trefoil Therapeutics
- AERIE PHARMACEUTICALS, INC.
- Price Vision Group
- ProQR Therapeutics
- Emmecell
- Pfizer Inc.
- GlaxoSmithKline plc
- Bausch Health Companies Inc.
- Bayer AG
- Allergan
- Teva Pharmaceutical Industries Ltd.
- Merck & Co., Inc.
- Novartis AG
Recent Development
In November 2022, Aerie Pharmaceuticals, Inc. has been successfully acquired by Alcon, a leader in worldwide eye care committed to helping people to see brilliantly. Thanks to its expanding portfolio of supplied pharmaceuticals and development pipeline, Alcon is now more prevalent in the ophthalmic pharmaceutical sector.
September 2022: An exclusive license partnership for ocular endothelial cell regeneration therapy in the region of China was reached by Celregen and Cellusion Inc.
Market Overview:
Fuchs endothelial corneal dystrophy (FECD) is another term for corneal degeneration. Affected is the thin cell layer that lines the back of the tissue layer. The term "endothelium" is frequently used to describe this layer. When these cells begin to disappear, illness rapidly follows. The cells help to remove the excess fluid from the tissue layer. As more tissues decline the tissue layer fills with fluid, causing edema and an unclear cornea. A form of endothelial dystrophy that affects the tissue layer on the front surface of the attention is Fuchs endothelial dystrophy. A characteristic of Fuchs Endothelial Corneal Dystrophy in elderly adults is bilateral, asymmetrical, and slowly contracting corneal edema. Currently, there are several therapy options for FECD, including drugs, corneal transplantation, and Descemet membrane endothelial keratoplasty (DMEK). The majority of the market share is accounted for by corneal transplantation, which is the most frequently prescribed treatment for fuchs endothelial corneal dystrophy.
The fuchs endothelial corneal dystrophy market is driven by several reasons, including the fact that women are more likely than males to develop this condition, which often affects persons over the age of 50. The market for treatments for Fuchs' endothelial corneal dystrophy will benefit from increased research into cellular therapy strategies and rising demand for eye care over the projected period. Furthermore, many people might not be aware of global fuchs endothelial corneal dystrophy, its signs or symptoms, or the current therapies. This may cause the disease's identification and treatment to be delayed, which may lead to severe difficulties and vision impairment.
Buy Now Full Report: https://www.sphericalinsights.com/checkout/1711
Browse key industry insights spread across 200 pages with 100 market data tables and figures & charts from the report on “Global Fuchs Endothelial Corneal Dystrophy (FECD) Market Size, Share, and COVID-19 Impact Analysis, By Treatment (Medication, Surgery, Others), By Diagnosis (Cornea Examination and Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count, Others), By End-Users (Hospital, Specialty Clinics, Homecare, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022– 2032”. Get Detailed Report Description Here:
The surgery segment is dominating the market with the largest market share during the forecast period.
Based on the treatment, the global fuchs endothelial corneal dystrophy market is classified into medication, surgery, and others. Among these, the surgery segment is dominating the market during the forecast period owing to the surgery involving replacing the damaged endothelium layer of the cornea with healthy donor tissue and is the most widely used treatment for fuchs endothelial corneal dystrophy. While Descemet membrane endothelial keratoplasty (DMEK) only transplants the cornea's thin inner layer, traditional corneal transplantation involves the replacement of the entire cornea.
The cornea examination and grading segment is influencing the market with the largest market share over the forecast period.
Based on the diagnosis, the global fuchs endothelial corneal dystrophy market is bifurcated into cornea examination and grading, corneal tomography, corneal pachymetry, corneal cell count, and others. Among these segments, cornea examination and grading are holding the largest market share over the forecast period, owing to due to the significance of identifying the disease's severity in selecting the best course of treatment.
The hospital segment is influencing the market share growth during the forecast period.
Based on the end users, the global fuchs endothelial corneal dystrophy market is bifurcated into hospitals, specialty clinics, home care, & others. Among these, the hospital segment is expected to grow the market during the forecast period, due to the reason that the majority of patients with advanced fuchs endothelial corneal dystrophy require surgical treatment, which is frequently carried out in a hospital setting.
Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/1711
North America is dominating the market with the largest market share during the forecast period
North America is dominating the market growth of fuchs endothelial corneal dystrophy due to there being many significant key players present, people having a lot of money to spend, and the healthcare system being well-established. Moreover, increasing the illness incidence may dominate the growth of the market.
Europe is the leading market for fuchs endothelial corneal dystrophy, and it will continue to grow shortly due to the growing influence of organ donation programs, availability of various treatment options and prevention strategies, and growing government focus on organ donation policies.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the global market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major vendors in the Global Fuchs endothelial Corneal Dystrophy Market include Kowa Company, Ltd., Trefoil Therapeutics, AERIE PHARMACEUTICALS, INC., Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc, Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Novartis AG, and others market players.
Get Discount At @ https://www.sphericalinsights.com/request-discount/1711
Recent Development
In November 2022, Aerie Pharmaceuticals, Inc. has been successfully acquired by Alcon, a leader in worldwide eye care committed to helping people to see brilliantly. Thanks to its expanding portfolio of supplied pharmaceuticals and development pipeline, Alcon is now more prevalent in the ophthalmic pharmaceutical sector.
Browse Related Reports
Global Angina Pectoris Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors (ACE Inhibitors), Anti-Platelets, Others), By End Users (Hospital, Speciality Clinics, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030
https://www.sphericalinsights.com/reports/angina-pectoris-drugs-market
Global Primary Hyperoxaluria (PH) Treatment Market Size, Share, and COVID-19 Impact Analysis, By Type (Primary Hyperoxaluria Type I, Primary Hyperoxaluria Type II, Primary Hyperoxaluria Type III), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
https://www.sphericalinsights.com/reports/primary-hyperoxaluria-ph-treatment-market
Global Breast Cancer Market Size, Share, and COVID-19 Impact Analysis, By Cancer Type (Hormone Receptor, HER2+), By Therapy (Targeted Therapy, Hormonal Therapy, Surgery & Radiation Therapy, Biologic Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022 – 2032
https://www.sphericalinsights.com/reports/breast-cancer-market
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Follow Us: LinkedIn | Facebook | Twitter
